TABLE 2.
Characteristics of HIV-1-infected subjects enrolled in the GSK vaccine trial
| Characteristic | Value for: |
||
|---|---|---|---|
| Entire study population (n = 13) | Study population by treatment group |
||
| Vaccine (n = 8) | Placebo/adjuvant (n = 5) | ||
| Age (median, yr) | 48 | 49 | 41 |
| Gender (% male) | 69 | 50 | 100 |
| Median duration of ARTa (yr) | 11 | 11 | 11 |
| Median baseline CD4 cell counts (/mm3) | 760 | 768 | 731 |
Before study entry.